Skip to content

Supernus Pharmaceuticals SUPN Common stock, shares issued (in shares)

Common stock, shares issued (in shares) at other companies

AbbVie logo
AbbVieABBV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Bausch Health Companies logo
Bausch Health CompaniesBHC
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
Bausch + Lomb logo
Bausch + LombBLCO

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's common stock, shares issued (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's common stock, shares issued (in shares)?
Supernus Pharmaceuticals (SUPN) reported common stock, shares issued (in shares) of $58.04M in Q1 2026.
How has Supernus Pharmaceuticals's common stock, shares issued (in shares) changed year-over-year?
Supernus Pharmaceuticals's common stock, shares issued (in shares) increased by 3.7% year-over-year, from $55.99M to $58.04M.
What is the long-term trend for Supernus Pharmaceuticals's common stock, shares issued (in shares)?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's common stock, shares issued (in shares) has grown at a 1.6% compound annual growth rate (CAGR), from $53.18M to $57.46M.